Læknablaðið - 15.06.2004, Page 21

FRÆÐIGREINAR / NOTKUN TÍÐAHVARFAHORMÓNA
Heimildlr
1. Elíasson JH, Tryggvadóttir L, Tulinius H, Guðmundsson J.
Hormónameðferð kvenna á íslandi. Læknablaðið 1998; 84: 25-
31.
2. Greendale GA, Lee NP, Arriola ER. The menopause. Lancet
1999; 353:571-80.
3. Persson I, Adami HO, Bergkvist L, Lindgren A, Pettersson B,
Hoover R, et al. Risk of endometrial cancer after treatment
with oestrogens alone or in conjunction with progestogens:
results of a prospective study. BMJ 1989; 298:147-51.
4. Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer
C. Risks of breast and endometrial cancer after estrogen and
estrogen-progestin replacement. Cancer Causes Control 1999;
10: 253-60.
5. Pike MC, Ross RK. Progestins and menopause: epidemiological
studies of risks of endometrial and breast cancer. Steroids 2000;
65: 659-64.
6. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C. The
risk of breast cancer after estrogen and estrogen-progestin
replacement. N Engl J Med 1989; 321: 293-7.
7. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence
and mortality in women receiving estrogen and estrogen-
progestin replacement therapy - long-term follow-up of a
swedish cohort. Int J Cancer 1996; 67: 327-32.
8. Tryggvadóttir L, Tulinius H, Eyfjörð JE, Sigurvinsson T. Breast
cancer risk factors and age at diagnosis: an Icelandic cohort
study. Int J Cancer 2002; 98: 604-8.
9. Tryggvadóttir L, Ólafsdóttir EJ, Guðlaugsdóttir S, Thorlacius
S, Jónasson JG, Tulinius H, et al. BRCA2 mutation carriers,
reproductive factors and breast cancer risk. Breast Cancer Res
2003; 5: R121-8.
10. Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA,
Haslam SZ. Hormone replacement therapy with estrogen or
estrogen plus medroxyprogesterone acetate is associated with
increased epithelial proliferation in the normal postmenopausal
breast. J Clin Endocrinol Metab 1999; 84: 4559-65.
11. Beral V, Bull D, Doll R, Key T, Peto R, Reeves G, et al. Breast
cancer and hormone replacement therapy: collaborative
reanalysis of data from 51 epidemiological studies of 52,705
women with breast cancer and 108,411 women without breast
cancer. Lancet 1997; 350:1047-59.
12. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ,
Kooperberg C, Stefanick ML, et al. Risks and benefits of
estrogen plus progestin in healthy postmenopausal women:
principal results From the Women’s Health Initiative
randomized controlled trial. JAMA 2002; 288: 321-33.
13. Beral V, Banks E, Bull D, Reeves G. Breast cancer and
hormone-replacement therapy in the Million Women Study.
Lancet 2003; 362:419-27.
14. Skouby S. Consequenses for HRT following the HERS II
and WHI reports: the primum non nocere is important, but
translation into quo vadis is even more essential. Acta Obstet
Gynecol Scand 2002; 81: 793-8.
15. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B,
et al. Randomized trial of estrogen plus progestin for secondary
prevention of coronary heart disease in postmenopausal
women. Heart and Estrogen/progestin Replacement Study
(HERS) Research Group. JAMA 1998; 280: 605-13.
16. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M,
Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years
of hormone therapy: Heart and Estrogen/progestin Replacement
Study follow-up (HERS II). JAMA 2002; 288:49-57.
17. Guðmundsson JA. Hormónameðferð á breytingaskeiði
kvenna. Læknablaðið 2002; 11: 803-4.
18. Grodstein F, Manson JE, Stampfer MJ. Postmenopausal
hormone use and secondary prevention of coronary events in
the nurses’ health study. A prospective, observational study.
Ann Intern Med 2001; 135:1-8.
19. Guðmundsson S. Tilmæli landlæknis til lækna um meðferð
kvenna með samsettum tíðahvarfahormónum. In: Dreifibréf
Landlæknisembættisins 2002. www.landlaeknir.is
20. Gottlieb S. FDA insists that oestrogen products for menopause
carry a waming. BMJ 2003; 326:126.
21. Tryggvadóttir L, Tulinius H, Lárusdóttir M. A decline and a
halt in mean age at menarche in Iceland. Ann Hum Biol 1994;
21:179-86.
22. Hagvangur. ÁrsskýrslaTóbaksvamamefndar. Reykjavík: Tóbaks-
varnarnefnd; 1996.
23. Hagvangur. Árskýrsla Tóbaksvamamefndar. Reykjavík: Tóbaks-
varnamefnd; 1997.
24. PricewaterhouseCoopers. Reykingar á íslandi, Ársskýrsla 1998.
Reykjavík: Tóbaksvarnamefnd; 1998.
25. PricewaterhouseCoopers. Reykingar á íslandi, Ársskýrsla 1999.
Reykjavík: Tóbaksvarnarnefnd; 1999.
26. PricewaterhouseCoopers. Reykingar á íslandi, Ársskýrsla 2000.
Reykjavík: Tóbaksvamamefnd; 2000.
27. PricewaterhouseCoopers. Reykingar á íslandi, Ársskýrsla 2001.
Reykjavík: Tóbaksvamamefnd; 2001.
28. Banks E, Bames I, Beral V, Reeves G. Patterns of use of
hormone replacement therapy in one million women in
Britain, 1996-2000. BJOG 2002; 109:1319-30.
29. Benediktsdóttir B, Tómasson K, Gíslason T. Einkenni breyt-
ingaskeiðs og meðferð þeirra hjá 50 ára íslenskum konum.
Læknablaðið 2000; 86:501-7.
30. Olesen C, Steffensen FH, Sorensen HT, Nielsen GL, Olsen
J, Bergman U. Low use of long-term hormone replacement
therapy in Denmark. Br J Clin Pharmacol 1999; 47: 323-8.
31. Lidegaard O. Use of oral contraceptives in Denmark 1980-
1990 and smoking habits among fertile women in 1990. Ugeskr
Laeger 1993; 155:3550-8.
32. Hardy R, Kuh D, Wadsworth M. Smoking, body mass index,
socioeconomic status and the menopausal transition in a
British national cohort. Int J Epidemiol 2000; 29: 845-51.
33. Greenberg G, Thompson SG, Meade TW. Relation between
cigarette smoking and use of hormonal replacement therapy
for menopausal symptoms. J Epidemiol Community Health
1987;41:26-9.
34. Bergmann J, Sigurðsson J, Sigurðsson K. Er hægt að bæta
þátttöku í leit að leghálskrabbameini? [Ágrip]. Læknaneminn
1992; 1:77.
Læknablaðið 2004/90 477